This is an Accepted Manuscript for Parasitology. This version may be subject to change during the production process. DOI: 10.1017/S0031182024000398

First report of apparent praziquantel resistance in *Dipylidium caninum* in Europe

Andreas W. Oehm[1], Anton Reiter[2], Angela Binz[3], Manuela Schnyder[1]

[1] Institute of Parasitology, Vetsuisse Faculty of Zurich, University of Zurich, Zurich, Switzerland

[2] Dammweg 94, 5000 Aarau, Switzerland

[3] Tierklinik Aarau West, Oberentfelden, Switzerland

Corresponding author: Manuela Schnyder, manuela.schnyder@uzh.ch

Word count: 2218

Abstract

Dipylidium caninum is a common tapeworm of dogs. Two cases of praziquantel resistance have been described in *D. caninum* in the United States. No further reports have been published to the authors´ knowledge. Here, the case of a dog imported to Switzerland from Spain with a history of chronic excretion of tapeworm proglottids and unresponsiveness to praziquantel treatments is reported. Clinical signs were mild (restlessness, tenesmus, anal pruritus, squashy faeces) and flea infestation could be ruled out. Infection with *D. caninum* was confirmed through morphological and genetic parasite identification. Different subsequently applied anthelmintic compounds and protocols, including epsiprantel, did not confer the desired effects. Proglottid shedding only stopped after oral mebendazole administration of 86.2 mg/kg body weight for five consecutive days. Clinical signs resolved and the dog remained coproscopically negative during a follow-up period of almost ten months after the last treatment. This case represents the first reported apparent praziquantel and epsiprantel resistance in *D. caninum* in Europe. Treatment was extremely challenging especially due to the limited availability of efficacious alternative compounds.

Key words: *Dipylidium caninum*; anthelmintic resistance; praziquantel/epsiprantel; dog; cestode

https://doi.org/10.1017/S0031182024000398 Published online by Cambridge University Press

Introduction

Dipylidium caninum (Cyclophyllidea, Dipylidiidae) is a common intestinal tapeworm of dogs with a worldwide distribution and with zoonotic potential (Gates and Nolan, 2009; Deplazes *et al*., 2021). Especially infants are prone to become infected after ingestion of infected fleas or lice (Elmonir *et al*., 2021) which act as intermediate hosts. In dogs, infections remain subclinical, or manifest with mild and unspecific clinical signs in most cases. Clinical signs may include anal pruritus causing an animal to rub its bottom along the ground, diarrhoea, weight loss, general restlessness, or tenesmus (Wani *et al*., 2015; Saini *et al*., 2016). The primary drug of choice to combat infections with *D. caninum* in dogs is praziquantel (at a single dose of at least 5 mg/kg body weight (BW) *per os* (p.o.) which usually shows high levels of efficacy (Schroeder *et al*., 2009; Saini *et al*., 2016; ESCCAP, 2021,). Another effective treatment option includes epsiprantel (at least 5.5 mg/kg BW p.o.) (Corwin *et al*., 1989; ESCCAP, 2021).

Up to date, anthelmintic resistance in canine and feline parasites has been of minor relevance and rather confined to regions and limited in scope, whereas it is a considerable problem in livestock and horses (Raza *et al*., 2018; von Samson-Himmelstjerna *et al*., 2021). Recently, an increasing frequency of reports on multiple anthelmintic resistance of *Ancylostoma caninum* in dog kennels in North America has been addressed as a major concern (Marsh and Lakritz, 2023). Moreover, two cases of possible praziquantel resistance have been reported in *D. caninum* infected dogs in the United States recently (Jesudoss Chelladurai *et al*., 2018; Loftus *et al*., 2022), emphasising the importance of this matter in companion animals as well. In Europe, no cases of anthelmintic resistance in companion animals have been reported yet. This case represents the first description of clinical resistance to praziquantel in *D. caninum* in Europe.

https://doi.org/10.1017/S0031182024000398 Published online by Cambridge University Press

Materials and Methods

Case presentation

A male, mixed breed Can de Chira dog imported from Spain of approximately 10 months of age and weighing 16.7 kg was presented with a history of chronic excretion of tapeworm proglottids after arrival in Switzerland. The dog was probably born in December 2021 around Monzón or Huesca (municipality of Aragon, Spain) and had been picked up from the street at the approximate age of four months together with other dogs of the same age. Subsequently, it had been kept at an animal shelter in Monzón. Clinical signs upon presentation were mild with general restlessness, tenesmus, slight anal pruritus, and occasionally squashy faeces. No evidence of flea infestation was present, and the dog had received treatment against ectoparasites (fluralaner, unknown dose) and helminths (praziquantel, febantel, pyrantel, unknown dose) before entering Switzerland. In Switzerland, the dog had been presented to the primary veterinarian and treated orally with 5.9 mg/kg body weight (BW) praziquantel, 5.9 mg/kg BW pyrantel, 18.0 mg/kg BW febantel (DrontalPlus®, Vétoquinol) twice within a period of two weeks as well as with 14.7 mg/kg BW fluralaner (Bravecto®, MSD Animal Health). Flea prophylaxis with fluralaner was pursued every 12 weeks as recommended by the manufacturer. Subsequently, proglottid excretion ceased, but re-started in an unchanged manner three weeks after the last praziquantel/pyrantel/febantel treatment. Hence, the dog received a single dose of 0.7 mg/kg BW milbemycinoxime and 7.4 mg/kg BW praziquantel (Milbemax®, Elanco Animal Health). Proglottid shedding continued and fenbendazole (Panacur®, MSD Animal Health) was administered orally for five consecutive days at a dose of 44 mg/kg BW. For four days, proglottid shedding ceased and 0.7 mg/kg BW milbemycinoxime and 7.4 mg/kg BW praziquantel (Milbemax®, Elanco Animal Health) were orally given twice within two weeks. Excretion of proglottids continued and 0.7 mg/kg BW milbemycinoxime and 7.4 mg/kg BW praziquantel (Milbemax®, Elanco Animal Health) was

https://doi.org/10.1017/S0031182024000398 Published online by Cambridge University Press

given orally once a week for a period of four weeks, yet excretion of cestode segments persisted.

Investigations

The presence of eggs/proglottids was examined via the adhesive tape method (Deplazes *et al*., 2021) and proglottids were also directly collected from the surface of the faecal samples. Furthermore, a combined sedimentation-flotation using saturated sodium-chloride solution with a specific weight of 1.2 g/cm^3 was performed on faecal samples (Deplazes *et al*., 2021). Proglottids were assessed microscopically and egg packets were pressed out from the proglottids in squash preparations. A multiplex PCR targeting the mitochondrially encoded 12S ribosomal RNA of non-*Echinococcus* cestodes (267 base pairs (bp) (Trachsel *et al*., 2007) was carried out to molecularly confirm the microscopic diagnosis.

Treatments and follow-up

The patient received 31.1 mg/kg BW pyrantel and 12.0 mg/kg BW epsiprantel (Dosalid®, Zoetis) in the first place. Next, 50.3 mg/kg BW mebendazole (Lendue Maxi®, Teknofarma S.r.l.) were administered on five consecutive days. Subsequently, 6.0 mg/kg BW praziquantel, 6.0 mg/kg pyrantel, and 24.0 mg/kg oxantel (Dolpac 10®, Vétoquinol) was initiated for a total of six days. One month after the last treatment with Dolpac 10®, a second round of mebendazole (Lendue Maxi®, Teknofarma S.r.l.) was given for five days, this time at an increased dose of 86.2 mg/kg. Contemporaneously, the animal owner recorded the development of proglottid excretion.

All the compounds mentioned in this section are not commercially available in Switzerland and were purchased in Portugal, Italy, or an international pharmacy after considering the regulations of off-label use in veterinary medicine in Switzerland and following

https://doi.org/10.1017/S0031182024000398 Published online by Cambridge University Press

the Swiss compendium of veterinary medicinal products (Tierarzneimittelkompendium CliniPharm, www.vetpharm.uzh.ch). The extension from three to five days of mebendazole treatment was derived from Miro *et al.* (2007). A detailed temporal pattern of anthelmintic treatments and proglottid excretion is compiled in Table 1.

Results

Based on gross morphological features of the proglottids (size of ~ 12mm x 3mm, mature genital organs, double genital pores slightly behind the middle of the lateral margins of each proglottid) and the eggs (capsulated and clustered in packets of 120 – 200 µm, with hexacanth embryo), *D. caninum* was diagnosed (Deplazes *et al.*, 2021) (Fig. 1). PCR confirmed an infection with *D. caninum*: a DNA segment of 259 bp was successfully sequenced and nucleotide basic local alignment search tool (BLAST) against the nucleotide collection of GenBank showed an identity of 98.07% (254/259 bp) with *D. caninum* from a canine host (accession number MH182479.1) (Jesudoss Chelladurai *et al.*, 2018). After epsiprantel/pyrantel (Dosalid®, Zoetis) treatment, proglottid shedding continued in an unchanged manner (Tab. 1). Mebendazole at a dose of 50.3 mg/kg BW on five consecutive days reduced the quantity of the excreted tapeworm segments. These were not superficially located on the faeces anymore but mixed within the faecal matter. Moreover, the proglottids appeared macerated and without motility. Re-appearance on the surface, however, occurred two weeks after the final administration of mebendazole. The combination praziquantel/pyrantel/oxantel (Dolpac 10®, Vétoquinol) did not stop the excretion of tapeworm segments. Eventually, proglottid shedding stopped from the second day of treatment with mebendazole 86.2 mg/kg BW (Tab. 1) and clinical signs (general restlessness, tenesmus, slight anal pruritus, occasionally squashy faeces) resolved. Moreover, the shedding of proglottids stopped and the dog remained coproscopically negative for a follow-up period of ten months.

https://doi.org/10.1017/S0031182024000398 Published online by Cambridge University Press

Discussion

This case represents the first written report of apparent praziquantel resistance in *D. caninum* in Europe. During the investigations for potential alternative anthelmintic treatments, further oral reports from veterinary parasitologists of Italy and Spain were mentioned to the authors (M. Schnyder, personal communication). To confirm that the infection was indeed caused by *D. caninum*, a combination of traditional parasitological and genetic methods was implemented.

Anthelmintic resistance is defined as the ability of helminth parasites to survive the administration of a certain previously effective drug (Prichard *et al.*, 1980; Sangster *et al.*, 2018). According to the VICH (Veterinary International Conference on Harmonization) guidelines (VICH, 2000, 2001), efficacy is described as a reduction of ≥ 90% of *D. caninum* scolices in controlled terminal studies. In the current case resistance may be suspected by the fact that multiple doses of praziquantel at the standard label treatment dose of 5 mg/kg BW (Schmid *et al.*, 2010) did not stop the continuous excretion of proglottids. Investigating the above-mentioned threshold for a drug to be considered efficacious in a controlled study would have required experimental infections: several factors (i.e. deriving from the individual dog, or being related to the environment, etc.) may in fact influence the presence and quantity of proglottids in faeces. Therefore, the absence of proglottids in this case did not allow to finally conclude on the efficacy of an anthelmintic agent, still, this represented the goal for the animal owner. Consequently, in the context of the current case, it was not possible to establish the resistance of the isolate by experimental infection of laboratory animals to further fathom the nature of this resistance, comparable to Jesudoss Chelladurai *et al.* (2018), who did also not establish the isolates in experimentally infected laboratory animals for further investigations either. The efficacy of anthelmintic treatment in the here reported case was instead

https://doi.org/10.1017/S0031182024000398 Published online by Cambridge University Press

continuously assessed by documenting the presence and quantity of proglottids excreted in faeces and by final determination of egg absence in faeces and by adhesive tape method. Accordingly, the isolate was not eliminated by the administration of praziquantel at the label dose of 5 mg/kg BW (Lloyd and Gemmell, 1992; Altreuther *et al.*; 2009, Schroeder *et al.*, 2009) nor by fenbendazole at a dosage of 44 mg/kg BW (Burke and Roberson, 1978) nor by epsiprantel (combined with pyrantel) at a dose of 12.0 mg/kg BW, i.e. more than twice as high as the recommended dose of 5.5 mg/kg BW (Corwin *et al.*, 1989). Interestingly, oral administration of praziquantel/pyrantel/febantel twice within a period of two weeks induced a 3-week suspension of proglottid excretion, suggesting some efficacy. The administration of praziquantel/pyrantel/oxantel had previously been successful in *D. caninum* infections (Grandemange *et al.*, 2007, Jesudoss Chelladurai *et al.*, 2018) and it was hypothesised that oxantel would exert a synergistic effect with the other compounds due to differences in drug action (Martin *et al.*, 2004, Jesudoss Chelladurai *et al.*, 2018). Yet, no reduction in the excretion of proglottids was noticed. In contrast, with mebendazole at the dosage of 50.3 mg/kg BW for five days, a clear reduction of the number of proglottids on faecal samples was observed, but single proglottids were present also after the last day of treatment. Previous studies have indicated an efficacy of oral mebendazole against cestodes (Vanparijs and Thienpont, 1973; Genchi *et al.*, 1990). Side effects of mebendazole such as vomiting and diarrhoea can occur already when therapeutic doses are administered. Moreover, the compound has been associated with hepatotoxicity visible as icterus, depression or anorexia and side effects commonly occur one day up until two weeks after administration (Polzin *et al.*, 1981; Swanson and Breider, 1982). In the current case, the dog was closely monitored, and no side effects of any kind were observed even when mebendazole was given at the increased dose. A thorough surveillance of dogs being treated with this compound seems reasonable, especially if administered off-label. As mebendazole had at least induced an apparent reduction of the number of excreted

https://doi.org/10.1017/S0031182024000398 Published online by Cambridge University Press

proglottids, it was decided to increase the dose to 86.2 mg/kg BW. This eventually turned out to be effective after the failure of multiple agents as well as mebendazole at a lower dose. However, it cannot be excluded that shedding of proglottids stopped due to reaching of the natural lifetime of the parasite (Jesudoss Chelladurai *et al.*, 2018). Yet, the macroscopic appearance of the proglottids and their motility evidently changed after initiation of mebendazole administration supporting the resistance of this *D. caninum* isolate to previous anthelmintic treatments and regardless of potential natural termination of infection.

One aspect to consider was the potential of flea infestation as a source of continuous reinfection of the patient. Consequently, the inability to eliminate the parasite could have been mistakenly interpreted as anthelmintic resistance with only temporary elimination of the infection. Yet, reinfection due to continued flea infestation of the dog appeared extremely unlikely as the dog was repeatedly treated against ectoparasites and in accordance with the information provided by the manufacturer the treatments were still exerting their flea-insecticidal activity during the investigations and their follow-up. Moreover, owners implemented intensive environmental surveillance for potential presence of fleas as well as environmental decontamination, although indications of flea infestation were absent. This is further corroborated by the fact that the dog remained negative for a follow-up period of more than three months after the last anthelmintic treatment as well as for an extended follow-up period of almost 10 months.

Owner compliance is an obviously relevant aspect in the context of suspected drug resistance when the administration of anthelmintics is delegated to the pet owner. This may include anthelmintics that are not administered in the right dose or frequency (Jesudoss Chelladurai *et al.*, 2018) or if the animal, unobserved, expels orally administered drugs. In the present case, owner compliance, involvement, and engagement were exceptionally high and due to the background of the owner as a medical practitioner, correct observation of the case,

https://doi.org/10.1017/S0031182024000398 Published online by Cambridge University Press

meticulous documentation as well as appropriate administration of medications was ensured.

Infections with *D. caninum* in humans are rare, associated with mild clinical signs such as discomfort or gastrointestinal disturbances (Taylor and Zitzmann, 2011; Portokalidou *et al.*, 2018), and mainly limited to cases where flea infestations and oral ingestion of fleas are present, e.g. in infants (Chappell *et al.*, 1990; Molina *et al.*, 2003; Jesudoss Chelladurai *et al.*, 2018). Given the interconnectedness of human and animal health, the emergence of anthelmintic resistance in *D. caninum* could pose a minimal risk to human health as well.

Conclusions

Future investigations are necessary to understand the extent of potential anthelmintic resistance present in *D. caninum* infecting dogs and cats, and the mechanisms involved to confer this resistance. Importantly, notifying the occurrence of similar cases with pharmacovigilance authorities will contribute to better data collection. Major challenges are represented by the limited availability of alternative effective compounds and their restricted availability depending on the country.

Acknowledgements. We wish to cordially acknowledge Stefania Zanet and Helder Cortez for their help with purchasing and shipping medications from Italy and Portugal, respectively.

Authors' contributions. Conceptualisation, MS; Investigation, AR, AB, AOE, MS; Methodology, MS, AR, AOE; Resources, MS, AR; writing-original draft, AOE, MS; writing – review and editing, AR, AB, AOE, MS. All authors have read and agreed to the submitted version of the article.

Financial support. This research received no specific grant from any funding agency,

https://doi.org/10.1017/S0031182024000398 Published online by Cambridge University Press

commercial or not-for-profit sectors.

Competing interests. The authors declare that there are no conflicts of interest.

Ethical standards. Informed and written consent for the anthelmintic treatments and the coproscopic analyses was obtained from the animal owner.

https://doi.org/10.1017/S0031182024000398 Published online by Cambridge University Press

References

Altreuther, G, Schimmel, A, Schroeder, I, Bach, T., Charles, S, Kok, DJ, Kraemer, F, Wolken, S, Yound, D and Krieger, KJ (2009) Efficacy of emodepside plus praziquantel tablets (Profender tablets for dogs) against mature and immature infections with *Toxocara canis* and *Toxascaris leonina* in dogs. *Parasitololgy Research* **105**, Suppl 1**,** S1-8. doi: 10.1007/s00436-009-1489-7.

Burke, TM and Roberson, EL (1978) Critical studies of fenbendazole suspension (10%) against naturally occurring helminth infections in dogs. *American Journal of Veterinary Research* **39,** 1799-1801.

Chappell, CL, Enos, JP and Penn, HM (1990) *Dipylidium caninum*, an underrecognized infection in infants and children. *Pediatric Infectious Diseases Journal* **9**, 745–747.

Corwin, RM, Green, SP and Keefe, TJ (1989) Dose titration and confirmation tests for determination of cesticidal efficacy of epsiprantel in dogs. *American Journal of Veterinary Research* **50,** 1076-7.

Deplazes, P, Joachim, A, Mathis, A, Strube, C, Taubert, A, von Samson-Himmelstjerna, G and Zahner, H (2021) *Parasitologie für die Tiermedizin,* 4th Edn. Stuttgart, Germany: Georg Thieme Verlag KG.

Elmonir, W, Elaadli, H, Amer, A, El-Sharkawy, H, Bessat, M, Mahmoud, SF, Atta, MS and El-Tras, WF (2021) Prevalence of intestinal parasitic infections and their associated risk factors among preschool and school children in Egypt. *PLoS One* **16,** e0258037. doi: 10.1371/journal.pone.0258037.

ESCCAP (European Scientific Counsel Companion. Animal Parasites) (2021) Worm control in dogs and cats. ESCCAP guideline 01. 6th ed. May 2021. https://www.esccap.org/uploads/docs/oc1bt50t_0778_ESCCAP_GL1_v15_1p.pdf (accessed 12 January 2024).

https://doi.org/10.1017/S0031182024000398 Published online by Cambridge University Press

Gates, MC and Nolan, TJ (2009) Endoparasite prevalence and recurrence across different age groups of dogs and cats. *Veterinary Parasitology* **166,** 153-8. doi: 10.1016/j.vetpar.2009.07.041.

Genchi, C, Traldi, G and Manfredi, MT (1990) Field trials of the anthelmintic efficacy of nitroscanate and mebendazole in dogs. *Veterinary Record* **126,** 77-80.

Grandemange, E, Claerebout, E, Genchi, C and Franc, M (2007) Field evaluation of the efficacy and the safety of a combination of oxantel/pyrantel/praziquantel in the treatment of naturally acquired gastrointestinal nematode and/or cestode infestations in dogs in Europe. *Veterinary Parasitology* **145,** 94-9. doi: 10.1016/j.vetpar.2006.11.013.

Jesudoss Chelladurai, J, Kifleyoannes, T, Scott, J and Brewer, MT (2018) Praziquantel resistance in the zoonotic cestode *Dipylidium caninum*. *American Journal of Tropical Medicine and Hygiene* **99,** 1201-1205. doi: 10.4269/ajtmh.18-0533.

Lloyd, S and Gemmell, MA (1992) Efficacy of a drug combination of praziquantel, pyrantel embonate, and febantel against helminth infections in dogs. *American Journal of Veterinary Research* **53,** 2272-3.

Loftus, JP., Acevedo, A, Bowman, DD, Liotta, JL, Wu, T and Zhu, M (2022) Elimination of probable praziquantel-resistant *Dipylidium caninum* with nitroscanate in a mixed-breed dog: a case report. *Parasites and Vectors* **15,** 438. doi: 10.1186/s13071-022-05559-2.

Marsh, AE and Lakritz J (2023) Reflecting on the past and fast forwarding to present day anthelmintic resistant *Ancylostoma caninum*–A critical issue we neglected to forecast. International Journal for Parasitology: Drugs and Drug Resistance **22** (2023) 36–43. doi.org/10.1016/j.ijpddr.2023.04.003

Martin, RJ, Clark, C., Trailovic, SM and Robertson, AP (2004) Oxantel is an N-type (methyridine and nicotine) agonist not an L-type (levamisole and pyrantel) agonist: classification of cholinergic anthelmintics in Ascaris. *International Journal of*

Parasitology **34,** 1083-90. doi: 10.1016/j.ijpara.2004.04.014.

Miro, G, Mateo, M, Montoya, A. Vela, E, Calonge, R (2007) Survey of intestinal parasites in stray dogs in the Madrid area and comparison of the efficacy of three anthelmintics in naturally infected dogs. *Parasitol Research* **100**, 317-320.

Molina, CP, Ogburn, J and Adegboyega P (2003) Infection by *Dipylidium caninum* in an infant. *Archives of Pathology and Laboratory Medicine* **127**, e157–e159. doi:10.5858/2003-127-e157-IBDCIA.

Polzin, DJ, Stowe, CM, O'Leary, TP, Stevens, JB and Hardy, RM (1981) Acute hepatic necrosis associated with the administration of mebendazole to dogs. *Journal of the American Veterinary Medical Association* **179,** 1013-6.

Portokalidou, S, Gkentzi, D, Stamouli, V, Varvarigou, A, Marangos, M, Spiliopoulou, I and Dimitriou, G (2018) *Dipylidium caninum infection* in children: clinical presentation and therapeutic challenges. *Pediatric Infectious Disease Journal* 38, e158–e159. doi: 10.1097/INF.0000000000002235.

Prichard, RK, Hall, CA, Kelly, JD, Martin, IC and Donald, AD (1980) The problem of anthelmintic resistance in nematodes. *Australian Veterinary Journal* **56,** 239-51. doi: 10.1111/j.1751-0813.1980.tb15983.x.

Raza, A, Rand, J, Qamar, AG, Jabbar, A and Kopp, S (2018) Gastrointestinal parasites in shelter dogs: Occurrence, pathology, treatment and risk to shelter workers. *Animals (Basel)* **8**, 108. doi: 10.3390/ani8070108.

Saini, VK, Gupta, S, Kasondra, A, Rakesh, RL and Latchumikanthan, A (2016) Diagnosis and therapeutic management of *Dipylidium caninum* in dogs: a case report. *Journal of Parasitic Disease* **40,** 1426-1428. doi: 10.1007/s12639-015-0706-9.

Sangster, NC, Cowling, A and Woddgate, RG (2018) Ten events that defined anthelmintic resistance research. *Trends in Parasitology* **34,** 553-563. doi: 10.1016/j.pt.2018.05.001.

https://doi.org/10.1017/S0031182024000398 Published online by Cambridge University Press

Schmid, K, Rohdich, N, Zschiesche, E, Kok, DJ and Allan, MJ (2010) Efficacy, safety and palatability of a new broad-spectrum anthelmintic formulation in dogs. *Veterinary Record* **167,** 647-51. doi: 10.1136/vr.c4661.

Schroeder, I, Altreuther, G, Schimmel, A, Deplazes, P, Kok, DJ, Schnyder, M and Krieger, KJ (2009) Efficacy of emodepside plus praziquantel tablets (Profender tablets for dogs) against mature and immature cestode infections in dogs. *Parasitology Research* **105** Suppl 1**,** S31-8. doi: 10.1007/s00436-009-1493-y.

Swanson, JF and Breider, MA (1982) Hepatic failure following mebendazole administration to a dog. *Journal of the American Veterinary Medical Association,* **181,** 72-3.

Taylor, T and Zitzmann, MB (2011) *Dipylidium caninum* in a 4-month old male. *Journal of Clinical Laboratory Science* **24**, 212-4.

Trachsel, D, Deplazes, P and Mathis, A (2007) Identification of taeniid eggs in the faeces from carnivores based on multiplex PCR using targets in mitochondrial DNA. *Parasitology* **134,** 911-20. doi: 10.1017/S0031182007002235.

Vanparijs, O and Thienpont, D (1973) [Anthelmintic effect of mebendazole against nematodes and cestodes in dogs]. *Deutsche Tierärztliche Wochenschrift* **80,** 320-2.

VICH (International Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products) (2000) Efficacy of anthelmintics: general requirements. Guideline 7. https://www.vichsec.org/en/guidelines.html (Accessed 5 March 2024).

VICH (International Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products) (2001) Efficacy of anthelmintics: specific recommendations for canines. Guideline 19. https://www.vichsec.org/en/guidelines.html (Accessed 5 March 2024).

Von Samson-Himmelstjerna, G, Thompson, RA, Krücken, J, Grant, W, Bowman, DD,

https://doi.org/10.1017/S0031182024000398 Published online by Cambridge University Press

Schnyder, M and Deplazes, P (2021) Spread of anthelmintic resistance in intestinal helminths of dogs and cats is currently less pronounced than in ruminants and horses - Yet it is of major concern. *International Journal for Parasitology Drugs and Drug Resistance* **17,** 36-45. doi: 10.1016/j.ijpddr.2021.07.003.

Wani, ZA, Allaie, IM, Shah, BM, Raies, A, Athar, H and Junaid, S 2015. *Dipylidium caninum* infection in dogs infested with fleas. *Journal of Parasitic Diseases* **39,** 73-5. doi: 10.1007/s12639-013-0281-x.



Figure 1. Eggs clustered in packets with hexacanth embryo typical for *Dipylidium caninum*.

https://doi.org/10.1017/S0031182024000398 Published online by Cambridge University Press

Table 1. Observed proglottid shedding and administered medications after antiparasitic treatments with pyrantel, febantel, milbemycinoxime, fenbendazole and fluralaner, and unsuccessful treatments with praziquantel administered to a dog infected with *Dipylidium caninum*. Proglottid shedding stopped for at least 10 months after the last mebendazole administration.

Date	Number of proglottids		Anthelmintic treatments (compounds, commercial name, company, country of origin)
	Assessment time		
	Morning	Afternoon/ Evening	
16/02/2023	Not observed	1	
17/02/2023	9	0	
18/02/2023	10	0	
19/02/2023	1	3	
20/02/2023	13	0	
21/02/2023	5	0	
22/02/2023	16	1	
23/02/2023	0	>20	
24/02/2023	8	0	
25/02/2023	8	0	
26/02/2023	>16	9	
27/02/2023	12	6	Epsiprantel, 12.0 mg/kg BW / Pyrantel 31.1 mg/kg BW p.o. (Dosalid®, Zoetis, Portugal)
28/02/2023	1	0	
01/03/2023	4	0	
02/03/2023	9	2	
03/03/2023	5	0	
04/03/2023	15	0	
05/03/2023	21	Not observed	
06/03/2023	13	0	Mebendazole 50.3 mg/kg BW p.o.
07/03/2023	>7[b]	0	Mebendazole 50.3 mg/kg BW p.o. (Lendue Maxi®, Teknofarma S.r.l., Italy)
08/03/2023	0	0	Mebendazole 50.3 mg/kg BW p.o.
09/03/2023	0	0	Mebendazole 50.3 mg/kg BW p.o.
10/03/2023	0	0	Mebendazole 50.3 mg/kg BW p.o.
23/03.2023	1	0	
24/03.2023	0	0	
25/03.2023	1	0	

https://doi.org/10.1017/S0031182024000398 Published online by Cambridge University Press

26/03.2023	1	0	
27/03.2023	3	0	
28/03.2023	2	0	
29/03.2023	2	0	
30/03.2023	2	0	
01/04/2023	0	0	
02/04/2023	0	0	
03/04/2023	0	0	
04/04/2023	8	0	Praziquantel 6.0 mg/kg BW Pyrantel 6.0 mg/kg BW Oxantel 24.0 mg/kg p.o. (Dolpac 10®, Vétoquinol, international pharmacy)
05/04/2023	5	5	Praziquantel 6.0 mg/kg BW Pyrantel 6.0 mg/kg BW Oxantel 24.0 mg/kg p.o.
06/04/2023	2	2	Praziquantel 6.0 mg/kg BW Pyrantel 6.0 mg/kg BW Oxantel 24.0 mg/kg p.o.
07/04/2023	2	0	Praziquantel 6.0 mg/kg BW Pyrantel 6.0 mg/kg BW Oxantel 24.0 mg/kg p.o.
08/04/2023	4	1	Praziquantel 6.0 mg/kg BW Pyrantel 6.0 mg/kg BW Oxantel 24.0 mg/kg p.o.
09/04/2023	8	0	Praziquantel 6.0 mg/kg BW Pyrantel 6.0 mg/kg BW Oxantel 24.0 mg/kg p.o.
10/04/2023	0	0	
11/04/2023	20	0	
12/04/2023	0	0	
13/04/2023	0	0	
14/04/2023	6	0	
15/04/2023	7	0	
16/04/2023	9	0	
17/04/2023	4	4	
18/04/2023	9	0	
19/04/2023	28	0	
22/04/2023	9	0	
23/04/2023	5	0	
24/04/2023	10	0	
25/04/2023	15	0	
26/04/2023	1	0	
27/04/2023	10	0	
28/04/2023	2	0	

https://doi.org/10.1017/S0031182024000398 Published online by Cambridge University Press

29/04/2023	10	0	
30/04/2023	11	0	
01/05/2023	10	0	
02/05/2023	1	0	
03/05/2023	8	0	
04/05/2023	8	0	
05/05/2023	7	0	
06/05/2023	5	0	
07/05/2023	5	0	
08/05/2023	8	0	
09/05/2023	6	0	
10/05/2023	3	0	
11/05/2023	5	0	Mebendazole 86.2 mg/kg BW p.o. (Lendue Maxi®, Teknofarma S.r.l., Italy)
12/05/2023	0	0	Mebendazole 86.2 mg/kg BW p.o.
13/05/2023	0	0	Mebendazole 86.2 mg/kg BW p.o.
14/05/2023	0	0	Mebendazole 86.2 mg/kg BW p.o.
15/05/2023	0	0	Mebendazole 86.2 mg/kg BW p.o.
16/05/2023	0	0	Mebendazole 28.7 mg/kg BW p.o.

[a] BW body weight
[b] at his point, proglottids were not superficially located on the faeces but rather mixed within the faecal matter and they seem macerated without motility

https://doi.org/10.1017/S0031182024000398 Published online by Cambridge University Press